Clinical trials: sponsored by Intra-Cellular Therapies, Inc.
- Lead sponsor (exact) Intra-Cellular Therapies, Inc.
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Volunteers
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.
- Trial name
- NCT06299410
- Testing
- ITI-1284 10 mg, ITI-1284 20 mg
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
The study will be conducted as a single-center, randomized, double-blind, placebo-controlled, ascending dose study in up to 4 sequential cohorts of healthy subjects.
- Trial name
- NCT05732194
- Testing
- ITI-333
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
This is an open-label, single-dose study of up to 4 dose levels of ITI-333 in healthy male and female subjects. Each cohort will enroll 6 subjects.
- Trial name
- NCT05470101
- Testing
- ITI-333
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects
ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of [14C]-ITI-1284…
- Trial name
- NCT06786286
- Testing
- [14C]-ITI-1284
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
The study will be conducted as a single-center, randomized, double-blind, placebo-controlled, ascending dose study in up to 8 sequential cohorts of healthy subjects.
- Trial name
- NCT04934124
- Testing
- ITI-333
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement
This is a single site, randomized, double-blind, placebo-controlled, within-subjects study design in healthy volunteers. Escalating single doses of ITI-214 will be evaluated using functional magnetic resonance imaging (fMRI) to…
- Trial name
- NCT03489772
- Testing
- ITI-214
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Alzheimer's Disease
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
A Phase 1b/2, Randomized, Double-blind, Placebo-Controlled, Multiple Oral Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients with Dementia
- Trial name
- NCT02078310
- Testing
- ITI-007
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.